New pill aims to tame heart disease inflammation

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female participants aged between 18 - 85 years (inclusive) at the start of screening will be included. * Subjects must have a body mass index (BMI) within the range of 18 - 45 kg/m2. BMI = Body weight (kg) / \[Height (m)\]2 * Documented spontaneous myocardial infarction (MI) (diagnosed according to the universal MI criteria with or without evidence of ST segment elevation) at least 30 days before the start of screening. * Participants must have hsCRP levels ≥ 2 mg/L at two timepoints during screening. Screening values must be separated by a minimum of 8 days. The initial hsCRP value must be a minimum of 30 days after the qualifying MI or after any percutaneous coronary intervention (PCI) performed separately from the qualifying MI. * For participants on statin therapy (HMG-CoA reductase inhibitor), as clinically indicated, participants must be on a stable regimen (at least 4 weeks before randomization), with no planned statin dose changes over the course of the trial treatment period. Unplanned statin dose changes during the trial treatment period may occur. Exclusion Criteria: * Patients receiving concomitant medications that are known to be strong or moderate inducers of cytochrome CYP2C9 enzyme and/or strong inducers of CYP3A, strong inhibitors of CYP2C9 and/or strong or moderate inhibitors of CYP3A and the treatment cannot be discontinued or switched to a different medication within 5 half-lives or 1 week (whichever is longer) prior to Day 1 and for the duration of the study. * Patients with suspected or proven immunocompromised state at screening * History of ongoing, chronic, or major recurrent infectious disease, at the discretion of the investigator, at the start of screening. * Use of any biologic drugs targeting the immune system within 26 weeks of Day 1 * Multi-vessel Coronary Artery Bypass Graft (CABG) surgery within the past 6 months prior to the start of screening. * Symptomatic Class IV heart failure (New York Heart Association) at the start of screening. * Planned coronary revascularization (PCI or CABG) or any other major surgical procedure during the study.